Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu
A phase 2 trial of Budigalimab, Livmoniplimab, Lenvatinib in hepatocellular carcinoma, run by AbbVie, active and no longer recruiting.
Overview
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) is a phase 2 interventional study registered as NCT05822752 by AbbVie, with 130 participants enrolled, started 2023-09-21 and due to reach its primary completion in 2026-11. Interventions recorded: Budigalimab, Livmoniplimab, Lenvatinib, Sorafenib. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Shares Livmoniplimab, Budigalimab, AbbVie (incl. ImmunoGen, Capstan), Hepatocellular carcinoma.
- TrialStudy to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Shares Livmoniplimab, Budigalimab, AbbVie (incl. ImmunoGen, Capstan).
- TrialStudy to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
Shares Livmoniplimab, Budigalimab, AbbVie (incl. ImmunoGen, Capstan).
- TrialREFLECT
Shares Sorafenib, Lenvatinib, Hepatocellular carcinoma.
- TrialSARAH and SIRveNIB
Shares Sorafenib, Hepatocellular carcinoma.
- TrialLEAP-002
Shares Lenvatinib, Hepatocellular carcinoma.
- TrialStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- TrialSHARP
Shares Sorafenib, Hepatocellular carcinoma.